 | | Vol. 13.30 – 2 August, 2022 |
| |
|
|
| The authors investigated whether mesenchymal stem cells, which provide an essential niche for long-term HSCs in the bone marrow, resided in the aorta–gonad–mesonephros and contributed to the development of the dorsal aorta and endothelial-to-hematopoietic transition.
[Nature Cell Biology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that enzyme sphingosine kinase 2, which generates the lipid metabolite sphingosine-1-phosphate, was highly expressed in HSCs.
[Blood] |
|
|
|
| Scientists conditionally deleted Xist in hematopoietic system of mice and reported differentiation and cell cycle defects in female hematopoietic stem and progenitor cells.
[Nature Communications] |
|
|
|
| Researchers reported that oxysterol-binding protein-related protein 4 L was expressed in adult T cell leukemia cells but not normal T cells.
[Nature Communications] |
|
|
|
| The authors established a mDia1/miR-146a double knockout (DKO) mouse model phenocopying myelodysplastic syndromes, and found that most of the DKO mice underwent leukemic transformation at 12-14 months of age.
[Journal of Clinical Investigation] |
|
|
|
| SLIT2 promoter methylation was markedly increased in myelodysplastic neoplasm/AML patients compared with controls and was correlated with poor clinical phenotype and outcome.
[Leukemia] |
|
|
|
| To target drug-resistant primitive leukemic cells better, scientists designed a CD34/CD3 bi-specific T cell engager and characterized its anti-leukemia potential in vitro, ex vivo, and in vivo.
[Haematologica] |
|
|
|
| Researchers have previously demonstrated an HSC-supportive function for GATA3 within the sympathetic nervous system and the sub-aortic mesenchyme, but showed here that it also played a cell-intrinsic role during the endothelial-to-hematopoietic transition.
[Stem Cell Reports] |
|
|
|
| Investigators developed an intravital imaging method to visualize bone marrow in neonatal long bones formed by endochondral ossification which is essential for HSC niche formation.
[Communications Biology] |
|
|
|
| | Scientists identified two cell surface proteins expressed on AML blasts of many patients that could represent novel targets for immunologic therapies, and confirmed these targets via flow cytometry.
[Blood] |
|
|
|
|
| The authors summarize the preclinical and clinical rationale for pevonedistat in MDS and AML, review the clinical data of this agent alone and in combination with hypomethylating agents to date, and highlight potential future directions for this agent in myeloid malignancies.
[Therapeutic Advances in Hematology] |
|
|
|
|
| Mission Bio, Inc. announced the initial availability of the industry’s first assay capable of determining measurable residual disease in cancer down to the level of individual cells.
[Mission Bio.] |
|
|
|
|
| December 3-7, 2022
Washington, DC, United States |
|
|
|
|
|
| | National Institutes of Health – Bethesda, Maryland, United States |
|
|
|
| | Warsaw University of Technology – Warsaw, Poland |
|
|
|
| | Institute for Research in Biomedicine – Barcelona, Spain |
|
|
|
| | The Chinese University of Hong Kong – Hong Kong, China |
|
|
|
| | Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
